Q3 FY26 revenue rose 23% year-over-year to $118.4M, with gross margin improving to 52.8%. FY26 revenue guidance was raised to $456–$457M, and adjusted EBITDA breakeven is expected in Q4. Net loss was $35.1M, impacted by a prior-year gain from a business spin-out.Original document: Twist Bioscience…
Q3 FY26 revenue rose 23% year-over-year to $118.4M, with gross margin improving to 52.8%. FY26 revenue guidance was raised to $456–$457M, and adjusted EBITDA breakeven is expected in Q4. Net loss was $35.1M, impacted by a prior-year gain from a business spin-out.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
